Fubotv earnings beat by $0.10, revenue topped estimates
Douglas F. Kling, the Chief Operating Officer of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), recently sold 16,539 ordinary shares in a transaction dated March 26, 2025. The shares were sold at prices ranging from $22.75 to $23.20 per share, amounting to approximately $376,000. Following this transaction, Kling holds 44,000 shares directly. The sale comes amid a strong six-month performance for NAMS, with the stock up 38% despite showing contrarian movement patterns against the broader market, according to InvestingPro data.
The sale was part of a series of transactions involving restricted stock units (RSUs) and ordinary shares. Kling acquired 16,539 ordinary shares through the vesting of RSUs, which were fully vested upon grant. These RSUs were granted as part of an earnout agreement following a business combination, where certain option holders received RSUs if specific clinical development milestones were achieved. The company maintains a strong financial position with a healthy current ratio of 8.08 and minimal debt on its balance sheet.
A portion of the shares sold was used to satisfy tax withholding obligations arising from the vesting of the RSUs. After the completion of these transactions, Kling’s direct ownership stands at 44,000 ordinary shares in the company. With analyst price targets ranging from $36.69 to $53.56, suggesting potential upside, investors can access detailed valuation analysis and 8 additional key insights through InvestingPro’s comprehensive research reports.
In other recent news, NewAmsterdam Pharma has reported strong financial health with a cash position of $835 million, following a successful public offering. The company is gearing up for global regulatory submissions of its cholesterol-lowering drug candidate, obicetrapib, after positive top-line results from three Phase 3 trials. Notably, the BROADWAY trial showed a significant reduction in major adverse cardiovascular events with a safety profile comparable to placebo. Scotiabank (TSX:BNS) has raised its price target for NewAmsterdam Pharma to $52, highlighting the potential for the company’s CETP inhibitor, obicetrapib, to make a significant impact in the cardiovascular disease market. Meanwhile, H.C. Wainwright initiated coverage with a Buy rating and a $48 price target, emphasizing obicetrapib’s potential as a game-changer for patients not meeting cholesterol goals with statins. The firm expects the ongoing PREVAIL study to demonstrate a 25% or greater benefit in major adverse cardiac events. NewAmsterdam Pharma is also preparing for the U.S. and European launches of obicetrapib, pending regulatory approval. The company’s strategic priorities for 2025 align with its mission to improve care for patients with metabolic diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.